117 related articles for article (PubMed ID: 9003465)
1. Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation.
Ino K; Bierman PJ; Varney ML; Heimann DG; Kuszynski CA; Walker SA; Talmadge JE
Cancer Immunol Immunother; 1996 Dec; 43(4):206-12. PubMed ID: 9003465
[TBL] [Abstract][Full Text] [Related]
2. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
3. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
4. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation.
Nagler A; Shur I; Barak V; Fabian I
Leuk Res; 1996 Aug; 20(8):637-43. PubMed ID: 8913316
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
8. Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Castenskiold EC; Kelsey SM; Collins PW; Coldwell RD; Allen PD; Side LE; Makin HL; Goldstone AH; Newland AC
Bone Marrow Transplant; 1995 Jun; 15(6):879-84. PubMed ID: 7581085
[TBL] [Abstract][Full Text] [Related]
9. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
10. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
[TBL] [Abstract][Full Text] [Related]
11. Influence of Bestatin, a new immunomodulator, on various functions of human monocytes.
Jarstrand C; Blomgren H
J Clin Lab Immunol; 1982 Dec; 9(3):193-8. PubMed ID: 7166751
[TBL] [Abstract][Full Text] [Related]
12. IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency.
Ruppert J; Friedrichs D; Xu H; Peters JH
Immunobiology; 1991 Aug; 182(5):449-64. PubMed ID: 1717365
[TBL] [Abstract][Full Text] [Related]
13. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
15. Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: what is the optimal timing?
Ener RA; Meglathery SB; Cuhaci B; Topolsky D; Styler MJ; Crilley P; Brodsky I; Kahn SB; King RS
Am J Clin Oncol; 2001 Feb; 24(1):19-25. PubMed ID: 11232944
[TBL] [Abstract][Full Text] [Related]
16. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma.
Haas R; Ehrhardt R; Witt B; Goldschmidt H; Hohaus S; Pförsich M; Ehrlich H; Färber L; Hunstein W
Bone Marrow Transplant; 1993 Dec; 12(6):643-9. PubMed ID: 7511017
[TBL] [Abstract][Full Text] [Related]
17. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow.
Schriber JR; Negrin RS; Chao NJ; Long GD; Horning SJ; Blume KG
Leukemia; 1993 Oct; 7(10):1491-5. PubMed ID: 7692189
[TBL] [Abstract][Full Text] [Related]
19. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
[TBL] [Abstract][Full Text] [Related]
20. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
